<DOC>
	<DOC>NCT01666613</DOC>
	<brief_summary>The purpose of this study is to look at drug levels of AZD8683 in blood when the drug is administered in different ways - orally, intravenously or inhaled (with two different devices), to healthy subjects</brief_summary>
	<brief_title>A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD8683 When Administered in Different Ways</brief_title>
	<detailed_description>A Phase I, Single-centre, Open-label, Partly Randomised, Cross-over Single Dose Study in Healthy Volunteers to Evaluate the Absolute Pulmonary Bioavailability of AZD8683 when Administered Inhaled via a New Dry Powder Inhaler and via Turbuhalerâ„¢</detailed_description>
	<criteria>Healthy males or women of nonchildbearing potential aged 1845 years inclusive with suitable veins for cannulation or repeated vein puncture Have a body mass index (BMI) between 19 and 30 kg/m2 (inclusive) and weight between 50 and 100 kg (inclusive) Be able to inhale from the inhaler devices used in the study. History of any clinically significant disease or disorder Current smokers Any clinically relevant abnormal findings in physical examination or laboratory values.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Phase I, Healthy volunteers, pharmacokinetics</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>AUC</keyword>
</DOC>